Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Matthew Pauls Insider Profile
4 Followers
Matthew Pauls, President & CEO, Director at Strongbridge Biopharma, holds 6.50K shares in Soleno Therapeutics (Ticker: SLNO), holds 1.28M shares in Savara (Ticker: SVRA), holds 0.00 shares in Zyla Life Sciences (Ticker: ZCOR).
Matthew Pauls Strongbridge Biopharma (SBBP)President & CEO, Director
Strongbridge Biopharma (SBBP)
President & CEO, Director
Ranked #10,240 out of 99,218 Corporate Insiders
Profitable Transactions
5 out of 6 Profitable Transactions
Average Return
+27.70%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Matthew Pauls holds in companies
Most Profitable Insider Trade
The most profitable trade made by Matthew Pauls
Matthew Pauls's Trading History
Strongbridge Biopharma
Feb 22, 2019
―
Uninformative Buy
―
$145.22K
Savara
Dec 29, 2023
CEO, Director
Uninformative Sell
―
$5.10M
Zyla Life Sciences
May 21, 2020
―
Uninformative Sell
―
$0.00
Soleno Therapeutics
Jun 10, 2024
Director
Uninformative Buy
―
$370.82K
Insmed
―
CCO
―
$0.00
List of latest transactions for each holding click on a transaction to see Matthew Pauls's performance on stock
You May Also Like
Matthew Pauls insider profile FAQ
What is the percentage of profitable transactions made by Matthew Pauls?
The percentage of profitable transactions made by Matthew Pauls is 83%.
What is the average return per transaction made by Matthew Pauls?
The average return per transaction made by Matthew Pauls is 27.70%.
What stocks does Matthew Pauls hold?
Matthew Pauls holds: SBBP, SVRA, ZCOR, SLNO, INSM stocks.
What was Matthew Pauls’s latest transaction?
Matthew Pauls latest transaction was an Uninformative Buy of ―.
What was Matthew Pauls's most profitable transaction?
Matthew Pauls’s most profitable transaction was an Informative Buy of SVRA stock on December 8, 2021. The return on the trade was 53.30%.
What is Matthew Pauls's role in Strongbridge Biopharma?
Matthew Pauls's role in Strongbridge Biopharma is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.